In addition to our multiplexed, flow cytometry-based SARS-CoV-2 serology assay, FlowMetric is also offering the gold-standard ELISA-based test for the serological evaluation of SARS-CoV-2 exposure. This test detects the IgG antibodies targeting the S1 protein of the SARS-CoV-2 virus.
Serological testing identifies individuals who have mounted a humoral immune response after viral exposure, whether or not they became symptomatic.
FlowMetric’s SARS-CoV-2 IgG serology tests will enable employers to formulate safe & effective "Return to Work" initiatives for their workforce. Our serology tests provide a simple easy to read report showing whether an individual has generated IgG antibodies to the SARS-CoV-2 virus. The presence of these antibodies is highly indicative of past exposure and will be useful information for informed decision making on how to safely return employees to the workplace.
FlowMetric's assay does not diagnose COVID-19 disease, nor does it document infection, or immunity to the virus. We are offering this assay for research and clinical applications, in accordance with FDA guidelines.
FlowMetric’s decade of experience in immune system analysis for drug development is the foundation of our expertise in COVID-19 serology testing. We offer both our advanced multiplexed-flow cytometry test and the gold-standard ELISA assay, both of which are performed under our CLIA certified and CAP accredited.